Impact of Pelvic Lymph Node Dissection on Early Oncological Outcomes in Intermediate‐Risk Prostate Cancer Patients With Node‐Negative PSMA PET

Documenti analoghi

• Are NCCN and EAU Active Surveillance Criteria Reliable in Patients With ISUP Grade‐2 Intermediate‐Risk Prostate Cancer? A Novel Model Integrating MRI to Predict Adverse Pathology
  di: Serdar Madendere, et al.
  Pubblicazione: (2025)
• Can the Briganti 2019 nomogram be modified to predict lymph node metastasis risk in patients with prostate cancer detected with in‐bore biopsy?
  di: Serdar Madendere, et al.
  Pubblicazione: (2024)
• Clinicopathological Significance of Extranodal Adipose Tissue Invasion in Metastatic Lymph Nodes in Patients With Prostate Cancer
  di: Hirotaka Nagasaka, et al.
  Pubblicazione: (2024)
• The Clinical Significance of Gallium‐68 PSMA‐11 PET‐Derived SUVmax in the Management of Metastatic Hormone‐Sensitive Prostate Cancer
  di: Cevat İlteriş Kıkılı, et al.
  Pubblicazione: (2026)
• Machine learning and explainable artificial intelligence to predict pathologic stage in men with localized prostate cancer
  di: Hemal Semwal, et al.
  Pubblicazione: (2024)